Live
FierceBiotechAmgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 dataBioPharma DiveTwo biotechs raise a combined $556M in latest spurt of IPOsMerck & Co.Spotlight On: Merck & Co. maintains BD appetite ahead of $70B sales goal - FirstWord PharmaSiemens HealthineersSiemens Healthineers Faces a Reckoning: Diagnostics Sale, Spin-Off Delays, and a Stock at Rock Botto - AD HOC NEWSThermo FisherHow Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo FinanceSiemens HealthineersARPA-H awards Siemens Healthineers up to $60M for Flash radiotherapy - AuntMinnieIlluminaIllumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR NewswireScienceDeepfakes are everywhere. The godfather of digital forensics is fighting backEndpoints NewsFDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialEndpoints NewsKrazati fails confirmatory trial in colorectal cancer, putting approval at risk10x Genomics BlogWhy 10x Genomics Stock Is Surging Today - TipRanksFierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
Contenu indisponible. Consultez la source originale.